This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Michael A. Griffith Appointed To Repligen Board Of Directors

Repligen Corporation (NASDAQ:RGEN) today announced that Mr. Michael A. Griffith has been appointed to serve on the Company’s Board of Directors. Mr. Griffith, 53, has extensive leadership experience in the bioprocessing and biopharmaceutical industries, as well as significant commercial and investment banking expertise. Mr. Griffith currently serves as Chief Executive Officer of Laureate Biopharmaceutical Services, Inc. (Laureate Biopharma), a full-service contract manufacturing organization focused on the production and manufacture of biologic drugs for biopharmaceutical customers worldwide.

“Michael’s background in biologics manufacturing is particularly relevant to Repligen, and he also brings valuable financial markets acumen to the Board,” said Walter C. Herlihy, President and Chief Executive Officer of Repligen. “In light of the major commitment that we made to bioprocessing with the December acquisition of Novozymes Biopharma - now Repligen Sweden - we welcome Michael’s insight in helping to guide the integration and expansion of this core business. We value the expertise that Michael offers during this exciting time of Repligen’s transition to a fully integrated and commercially focused company.”

Mr. Griffith has held numerous executive level positions, including his current role since April 2010 as CEO and director of Laureate Biopharma. He is the founder of Aptuit, Inc., a global contract pharmaceutical research, development and manufacturing company, and from 2004 to 2008 served as the company’s CEO. From 1996 to 2000, Mr. Griffith was with ChiRex, Inc., where he initially served as Chief Financial Officer before being named the company’s Chairman and CEO. ChiRex was a Nasdaq-listed pharmaceutical contract development and manufacturing organization specializing in small-molecule drug substance development. Mr. Griffith was part of the team that led the initial public offering for ChiRex, which later sold for $600 million to Rhodia SA, a NYSE-listed, Paris-based specialty chemicals company. Mr. Griffith led the teams that built both Aptuit and ChiRex to become international pharmaceutical supply companies with over 2,700 and 600 employees, respectively. Between 2000 and 2004, he was a consultant to Rhodia and several private equity and pharmaceutical companies. Mr. Griffith for eight years served as Chairman of the Board and Chairman of the Executive Committee at Centrue Financial Corporation and Centrue Bank, a Nasdaq-listed commercial bank. Prior to his involvement in the biopharmaceutical industry, Mr. Griffith worked nearly 15 years as a commercial and investment banker at Bankers Trust and First Boston. He earned a Masters of Management from the Kellogg Graduate School of Management at Northwestern University, and a Bachelor of Science in Business Administration from the University of Kansas.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs